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ABSTRACT
Introduction: Risk stratification tools provide
valuable information to inform treatment
decisions. Existing algorithms for patients with
multiple myeloma (MM) were based on patients
with newly diagnosed disease, and these have
not been validated in the relapsed setting or in
routine clinical practice. We developed a risk
stratification algorithm (RSA) for patients with
MM at initiation of second-line (2L) treatment,
based on data from the Czech Registry of
Monoclonal Gammopathies.
Methods: Predictors of overall survival (OS) at
2L treatment were identified using Cox pro-
portional hazards models and backward selec-
tion. Risk scores were obtained by multiplying
the hazard ratios for each predictor. The
K-adaptive partitioning for survival (KAPS)
algorithm defined four groups of stratification
based on individual risk scores.
Results: Performance of the RSA was assessed
using Nagelkerke’s R2 test and Harrell’s concor-
dance index through Kaplan–Meier analysis of
OS data. Prognostic groups were successfully
defined based on real-world data. Use of a
multiplicative score based on Cox modeling
and KAPS to define cut-off values was effective.
Conclusion: Through innovative methods of
risk assessment and collaboration between
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physicians and statisticians, the RSA was cap-
able of stratifying patients at 2L treatment by
survival expectations. This approach can be
used to develop clinical decision-making tools
in other disease areas to improve patient
management.
Funding: Amgen Europe GmbH.
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Key Summary Points
Defining the prognosis of patients with
multiple myeloma (MM) is increasingly
challenging, and validated prognostic
tools are needed in MM to standardize risk
stratification of patients and ultimately
improve risk assessment.
Existing algorithms for patients with MM
are based on patients with newly
diagnosed disease, and these have not
been validated in the relapsed setting or in
routine clinical practice.
A risk stratification algorithm (RSA) has
been developed for patients with MM at
initiation of second-line (2L) treatment,
based on data from the Czech Registry of
Monoclonal Gammopathies.
The RSA uses 16 predictors to stratify
patients with MM at 2L treatment into
four risk groups with profoundly different
survival expectations.
This approach can be used to develop
clinical decision-making tools in other
disease areas to improve patient
management.
INTRODUCTION
Statistical tools capable of predicting risk can
provide valuable information for healthcare
professionals and patients and can potentially
lead to improved outcomes. Widely used
examples that have influenced clinical practice
include the Kattan prostate cancer nomogram
[1], the PREDICT online assessment tool [2, 3],
and disease activity indices for systemic lupus
erythematosus (SLE) [4, 5]. Recently, a phase 3
trial has shown that a web-based risk assessment
tool, which used patient-reported symptoms
and was sent to the oncologist between sched-
uled visits, improved the rate of early detection
of relapse in patients with lung cancer, which in
turn led to significant increases in overall sur-
vival (OS) in patients who used the tool than in
those who did not [6].
Assessing the risk of death and predicting
survival outcomes for patients with complex
diseases can be challenging. Multiple myeloma
(MM) is a complex malignancy that is hetero-
geneous in prognosis, response to treatment,
and drivers of disease progression [7, 8]; despite
this, staging algorithms have been developed
for patients with newly diagnosed MM, such as
the International Staging System (ISS). Data
from more than 5000 patients were analyzed
using a survival tree model to produce the ISS, a
three-group staging system. The ISS is based on
levels of serum b-2 microglobulin (Sb2M) and
serum albumin [9]. In 2015, a revised ISS (R-ISS)
was published that used additional factors, such
as cytogenetic abnormalities (CA) and lactate
dehydrogenase (LDH) levels, to define the
extent of disease progression in patients with
newly diagnosed MM [10]. The R-ISS used a Cox
proportional hazards model and the K-adaptive
partitioning for survival (KAPS) algorithm to
define the thresholds associated with each of
the three disease stages [10, 11].
Despite recent advances in treatment, almost
all patients with newly diagnosed MM will
relapse eventually [12, 13]. Prognostic infor-
mation obtained during first-line (1L) treatment
could influence prognosis and treatment deci-
sion-making when patients are entering second-
line (2L) treatment [7]; indeed, it has been
shown that the predictors of OS can change
between the initiation of 1L and 2L treatments
[14]. Therefore, the first relapse is an important
time during which physicians need further evi-
dence of patient frailty and disease severity.
To date, none of the staging algorithms for
MM have been validated in the relapsed setting.
Herein, we describe the approach taken and
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statistical methods employed to develop a risk
stratification algorithm (RSA) specifically for
patients with MM initiating 2L treatment, and
we compare the performance of the RSA with
that of existing MM staging algorithms.
METHODS
Selection of a Suitable Data Source
The Czech Registry of Monoclonal Gam-
mopathies (RMG) is one of the largest of its kind
and contains data on a substantial number of
patients with MM initiating 2L treatment [15],
as well as mature OS data and information on a
large number of parameters [15]. This RSA was
developed using validated and quality-con-
trolled data that were collected between May
2007 and April 2016. Informed consent was
granted in the original study of the RMG [15].
The data in this study are based on a previously
conducted study, and informed consent was
granted in the original study. Each center con-
tributing to the registry received approval by an
Institutional Review Board/Independent Ethics
Committee (IRB/IEC). Further information on
the ethical approval is detailed in the original
study.
Eligibility Criteria
The RSA included individuals aged C 18 years
who were given one or more doses of anti-
myeloma treatment after first relapse. Eligibility
for stem cell transplantation was not consid-
ered. Patients who died or were lost to follow-up
before initiating 2L treatment were excluded
from the analysis.
Development Strategy
Step 1: Selection of Candidate Predictors of OS
at the Initiation of 2L Treatment
Predictors of OS (Table 1) were identified by
literature analysis and by the findings from a
conceptual model of MM progression, which
was defined by a Delphi process involving
leading experts in MM [16, 17].
Step 2: Defining Parameters to Reflect Clinical
Relevance
Splitting predictors into categories can lead to
the omission of important information [18];
non-categorical variables were treated as con-
tinuous whenever possible. Martingale residuals
and restricted cubic splines were used to model
the relationships between continuous variables
and the risk of death. Fractional polynomials
and restricted cubic splines were used to assess
the shape of the associations between non-lin-
ear variables and risk of death. These methods
provide more flexible descriptions of the non-
linearity of continuous variables than other
procedures [19]. Current literature does not
contain data describing the shape of the rela-
tionships between prognostic factors and OS in
patients with MM. Therefore, the form of the
modeled associations between continuous vari-
ables and OS was reviewed by experts in MM to
assess whether the shape of the relationships
between prognostic factors and OS demon-
strated clinically meaningful associations.
Step 3: Imputation of Missing Values
Missing data for all but one of the parameters
(CA at diagnosis) were added through multiple
imputation by chained equations (using MICE,
a software package in R) to provide full data sets
for all patients in the RMG [20, 21]. Given that
data on CA are not routinely collected, a dif-
ferent imputation method was required that
would allow the risk of death associated with
not having CA data to be captured in the RSA.
An indicator method was selected in which
missing observations were set to a fixed value,
and an extra dummy variable was added to
indicate whether the value for that variable was
missing. However, patients who were lost to
follow-up and those who had not died after
initiation of 2L treatment were censored, and
dates of death were not estimated in the
imputation.
Five data sets were generated from the
relapsed/refractory population of the RMG
using an imputation algorithm. The selected
predictors and predictor effects on OS were
generally similar across data sets; however,
there is limited information in the literature on
methods for pooling the results of (backward)
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predictor selection from multiple imputed data
sets [22, 23]. Therefore, the third imputed data
set was chosen at random and used for devel-
opment of the optimized RSA.
Step 4: Selecting Independent Predictors of OS
Covariates that correlated strongly with other
candidate predictors (Pearson’s correlation
coefficient[0.40) were excluded. Backward
selection was used in combination with clinical
judgement for accurate prognostic model
building. Clinical judgement via a Delphi
process was used to preselect predictors before
backward selection and to validate the model
[17]. Backward selection was then performed in
which multivariable Cox regression models
were fitted with OS as the dependent variable,
with the predictors that emerged from Pearson’s
test as independent variables. The Akaike
information criterion was used to select
parameters for the RSA; however, studies have
demonstrated that automated statistical pre-
dictor selection can exclude parameters that are
known to have a strong independent effect on
Table 1 Candidate predictors of overall survival from initiation of 2L treatment
Age at 2La Treatment received in 1L
Sb2M at diagnosis Best response to 1L treatment
Sb2M at 2La Bone marrow plasma cell count at 2L
M-protein level at 2L Calcium level at 2L
Nature of relapse at 2L Cytogenetic abnormalitiesb at diagnosisa
New bone lesions at 2L Creatinine level at 2L
Neuropathy during 1L Duration of response in 1L
Refractory to 1L regimensa,c ECOG PS at 2La
Serum albumin level at diagnosis Extramedullary disease at 2L
Serum albumin level at 2L Hemoglobin level at 2L
Severe toxicities during 1L Infection during 1L treatment
SCT status at 2L LDH level at diagnosis
Thrombocyte count at 2L LDH level at 2La
Time to initiation of 2L treatmentd Time since diagnosis at 2L
Time to progression at 2Le
Predictors retained in the model are marked in bold text
1L First-line, 2L second-line, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehy-
drogenase, Sb2M serum b-2 microglobulin, SCT stem cell transplantation
a To be included in the model regardless of statistical significance
b High-risk cytogenetic abnormalities were defined as the presence of del(17p) and/or t(4:14) and/or (14;16) and were
based on fluorescence in situ hybridization (FISH), with plasma cell selection
c Refractory to the 1L regimen status was defined as being either non-refractory, refractory to thalidomide, or refractory
regimens with new agents (comprising bortezomib ? thalidomide (n = 21), lenalidomide only (n = 20), bortezomib ?
lenalidomide (n = 2) and lenalidomide ? thalidomide (n = 1)
d To be included in the model regardless of statistical significance if time to progression was excluded by backward selection
e To be included in the model regardless of statistical significance if time to initiation of 2L treatment was excluded by
backward selection
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survival [18]. To prevent the omission of key
variables, a group of predictors with acknowl-
edged links to survival in patients with MM was
included in the model regardless of statistical
significance (Table 1).
Step 5: Calculating Patient-Specific Risk Scores
Risk scores were calculated for each individual
patient for each of the selected predictors. For
categorical variables, the hazard ratio (HR)
belonging to the patient-specific value was
used; for continuous variables, the log HR (b)
multiplied by the patient-specific value was
used (exp[b 9 patient value]). The resulting
predictor-specific risk scores were multiplied
with each other to produce a total risk score for
each patient. The resulting patient-specific total
risk score is continuous and can be interpreted
as the relative risk of death for a given patient
compared with a theoretical patient who has
the lowest predictor value for each parameter. It
is of note that baseline hazards were not relied
upon to derive the individual risk scores for the
RSA.
Step 6: Defining Risk Stratification Using
Patient-Specific Risk Score
A KAPS algorithm was used to define the risk
score boundaries between groups that would
provide statistically significantly differences in
OS for the RSA [11].
Step 7: Measuring the Performance of Cox
Models and Risk Stratification
Performance of the optimized RSA Cox model,
and the ISS and R-ISS Cox models, when applied
to the RMG data set, was assessed using
Nagelkerke’s R2 test, Harrell’s concordance
index (C-index), and integrated discriminations
improvement (IDI) [24]. Given that the opti-
mized RSA was derived from the same data set
in which it was tested, results for Nagelkerke’s
R2 test, the C-index and IDI data were adjusted
for optimism by bootstrapping [25]; the ISS and
R-ISS were developed using different data sets.
The RSA was designed to predict survival
from the initiation of 2L treatment; therefore,
the treatment regimen used after stratification
was not considered as a predictor. We assumed
that each patient would receive the best possi-
ble therapy, meaning that future treatment
should not bias the association of the predictors
with the outcome. This assumption should
have been tested using marginal structural
models; however, these were not feasible in the
development data set. Nevertheless, based on
the similar outcomes achieved by each regimen
within risk groups, we believe that the
assumption holds.
The optimized RSA, the ISS, and the R-ISS
were evaluated in the RMG data set using
Kaplan–Meier curves and HRs for OS from the
initiation of 2L treatment. P values for statistical
significance were obtained for HRs for OS and
for comparisons of OS between groups using the
log-rank test.
RESULTS
Patients
The RMG contained data on 1418 eligible
patients with MM who had begun 2L therapy.
Details on prior therapy have been reported
previously [26]. The longest duration of follow-
up was 103 months, and the median follow-up
(considering censoring for mortality) was 27.6
(95% confidence interval [CI] 25.1–30.1)
months. Details of baseline characteristics of
patients have been reported previously [26].
Identification and Coding of Candidate
Predictors
Twenty-nine candidate predictors were identi-
fied by literature searches and by the conceptual
model (Table 1). Parameters such as the pres-
ence of extramedullary disease or Eastern
Cooperative Oncology Group performance sta-
tus at the initiation of 2L treatment are cate-
gorical in nature and were treated as such in the
RSA (Table 2). Our intention was that none of
the continuous variables would be categorized
or dichotomized in the optimized RSA, but this
was considered to be inaccurate in some cases.
For example, the measurement of LDH levels is
subject to considerable variation among
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Table 2 Cox models showing selected predictors of overall survival in the risk stratification algorithm
Predictor of OSa
(at initiation of 2L
unless
stated otherwise)
Classification
of predictor
Categories/
thresholds
Backward selection,
HR (95% CI)
AIC = 9172.275
p value
Age, years Fully continuous NA 1.015 (1.007–1.023)f 0.0002
Albumin, g/dL Fully continuous NA 0.846 (0.745–0.960)f 0.0095
Bone marrow plasma cell
count, %
Fully continuous NA 1.008 (1.005–1.011)f \ 0.0001
Thrombocyte
count, 9 109
cells/L
Continuous with threshold (150 9 109 cells) 0.995 (0.992–0.997)f \ 0.0001
Sb2 M, mg/L Continuous with threshold (5.5 mg/L) 1.063 (0.993–1.138)f 0.0787
Sb2M at diagnosis, mg/L Continuous with threshold (5.5 mg/L) 1.090 (1.022–1.162)f 0.0084
LDH, U/L Continuous with clinically
established cut-off
B ULN Reference
[ULN 2.080 (1.651–2.622) \ 0.0001
LDH at diagnosis, U/L Continuous with clinically
established cut-off
B 360c Reference
[ 360 1.297 (0.960–1.752) 0.0904
Calcium, mmol/L Continuous with clinically
established cut-off
B 2.75 Reference
[ 2.75 1.406 (1.012–1.954) 0.0422
Time to next treatment,
months
Continuous with clinically
established cut-off
[ 24 Reference
B 24 1.112 (0.915–1.353) 0.2858
ECOG PS Categorical 0 Reference
1 1.667 (1.227–2.265) 0.0011
2 2.123 (1.520–2.964) \ 0.0001
3 or 4 3.708 (2.496–5.506) \ 0.0001
Cytogenetic
abnormalitiesb
at diagnosis
Categorical Standard risk Reference
High risk 1.643 (1.147–2.353) 0.0067
NA 1.081 (0.789–1.481) 0.6299
Extramedullary disease Categorical No Reference
Yes 2.331 (1.872–2.904) \ 0.0001
New bone lesions (X-ray) Categorical No new lesions Reference
[ 2 at diagnosis and
initiation
of 2Ld or new lesions
1.271 (1.075–1.502) 0.0049
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laboratories. Consequently, LDH could not be
regarded as a continuous parameter and was
treated as a binary variable for which the refer-
ence categories and high-risk categories were
below and above the upper limit of normal,
respectively. Analysis of the curves plotted to
show the relationships between the remaining
continuous variables and OS, using restricted
cubic splines (Fig. 1), highlighted that some of
the other continuous parameters could not be
treated as such in the model. The plot for time
to initiation of 2L treatment against OS (Fig. 1)
appeared to show that risk of death initially
increased as time to initiation of 2L treatment
increased; this was counterintuitive, and expert
opinion suggested that the spike in the curve
was not clinically meaningful. To ensure that
the HR associated with time to initiation of 2L
treatment was clinically meaningful, this
variable was dichotomized ([ 24 months
and C 24 months). When serum calcium level
was treated as a fully continuous variable, the
slope for risk of death continued to rise into the
normal range (2.20–2.75 mmol/L) (Fig. 1).
Experts advised that this did not reflect clinical
observations and that patients with calcium
levels in this range would not be regarded as
having an increased risk of death when initiat-
ing 2L treatment for MM. Calcium level was,
therefore, dichotomized and described in terms
of the presence or absence of hypercalcemia
(defined as calcium levels[ 2.75 mmol/L).
When measured at the initiation of 2L
treatment, age and serum albumin both exhib-
ited a linear relationship with risk of death
(Fig. 1). However, bone marrow plasma cell
count, thrombocyte count, and Sb2M (both at
diagnosis and at the initiation of 2L treatment,
Table 2 continued
Predictor of OSa
(at initiation of 2L unless
stated otherwise)
Classification
of predictor
Categories/
thresholds
Backward
selection,
HR (95% CI)
AIC = 9172.275
p value
Refractory status Categorical Non-refractory Reference
Refractory to
bortezomib
1.533
(1.202–1.955)
0.0006
Refractory to
thalidomide
1.186
(0.942–1.493)
0.1446
Refractory regimens
with new agentse
1.427
(0.961–2.120)
0.0776
Severe toxicities during 1L treatment
(any grade 3 or 4 toxicity)
Categorical No Reference
Yes 1.145
(0.984–1.332)
0.0797
AIC Akaike information criterion, CI confidence interval, HR hazard ratio; NA not applicable; OS, overall survival; RSA,
risk stratification algorithm; ULN, upper limit of normal
a At the initiation of 2L treatment unless otherwise stated
b High-risk cytogenetic abnormalities was defined as the presence of del(17p) and/or t(4:14) and/or (14;16) and were based
on FISH, with plasma cell selection
c ULN was 360 U/L in this data set
d Category comprises patients with accelerated osteoporosis/[ 2 lesions at diagnosis and 2L treatment
e Comprising bortezomib ? thalidomide (n = 21), lenalidomide only (n = 20), bortezomib ? lenalidomide (n = 2) and
lenalidomide ? thalidomide (n = 1)
f HR per unit change
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Fig. 1 Shape of the association of continuous predictors with overall survival, modeled using restricted cubic splines (three
knots). 2L Second-line, BM bone marrow, HR hazard ratio, Sb2M serum b-2 microglobulin
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unless specified otherwise) exhibited a non-lin-
ear relationship (Fig. 1). Bone marrow plasma
cell count proved difficult to evaluate non-lin-
early because values up to 10% were recorded as
0% in the data; therefore, linearity was
assumed, and bone marrow plasma cell count
was coded as fully continuous. We investigated
the use of three- or four-knot restrictive cubic
splines and fractional polynomials to define
curve shapes that would allow HRs to be
assigned for thrombocyte count and Sb2M.
Various fractional polynomial transformations
of each variable (x) were considered, including
xp in which p was set at - 2, - 1, - 0.5, 0 (i.e.
log[x]), 0.5, 1, 2 or 3. The functional form for
Sb2M and thrombocyte count was chosen using
a modified backward selection process that
identified the transformation with the best fit to
the data. Fractional polynomials gave the best
fit from a clinical standpoint, and this method
was used to define the curve shape for Sb2M
(p set at 2) and thrombocyte count (p set at
- 0.5) (Electronic Supplementary Material
[ESM] Fig. S1). When cubic splines were applied
to Sb2M level or thrombocyte count, a decline
in risk was suggested for extreme values com-
pared with elevated values (10 vs. 5–6 mg/L for
Sb2M;[400 9 109 vs. 300 9 109 cells/L for
thrombocyte count); however, the confidence
intervals (CIs) indicated a high degree of
uncertainty around the area of decline (Fig. 1).
The ultimate objective when developing the
RSA was to create a tool that could be used in
the clinical setting. The mathematical transfor-
mations required to derive the HRs for Sb2M
and thrombocyte count were deemed to be too
complex for clinical use, and a more practical
solution was sought. The curve shapes gener-
ated by the application of fractional polynomi-
als featured distinct gradient and plateau
regions. Based on these curve shapes, threshold
values at which the risk of death remained
constant could be defined using the devised
variable methods (Fig. 2) [27]. The curve for
Sb2M suggested a threshold of approximately
5.5 mg/L (Fig. 2), which was consistent with the
value used in the ISS and R-ISS, as well as with
expert opinion [9, 10]. No such clinically
established threshold exists for thrombocyte
count, but risk of death appeared to plateau
between 150 9 109 and 200 9 109 cells/L; any
value above this range can be considered to be a
normal count. Experts agreed that any value in
the plateau region would be in line with clinical
observations; therefore, to identify the opti-
mum cut-off, Cox models were run with the
threshold value set at various points within this
range. The best fit was observed when the
threshold level was 150 9 109 cells/L, and this
value was used in the optimized RSA.
Independent Predictors of OS
from the Initiation of 2L Treatment
Following elimination of parameters that cor-
related strongly with other candidate predictors
in the model and a backward selection process,
16 independent predictors of OS (at initiation of
2L unless stated otherwise) were identified
(Table 2). Of the variables that were pre-speci-
fied to be included in the RSA regardless of
statistical significance (Table 1), only time to
initiation of 2L treatment was forced into the
model. The calculation formula to measure risk
score is included in the Appendix in the ESM.
Cox Model Performance
The Nagelkerke’s R2 test score, which was
adjusted for optimism, was 0.23 for the opti-
mized RSA Cox model (possible scores range
between 0 and 1), and the C-index was 0.72 (a
perfectly discriminating model would have a
score of 1; a good discriminating model would
have a score of[0.70) (Table 3) [28].
Comparison of RSA Cox Model with ISS
and R-ISS
When analyzed in the RMG data set, the opti-
mized RSA Cox model outperformed the ISS and
R-ISS Cox models as measured by Nagelkerke’s
R2 test and C-index. The scores in the Nagelk-
erke’s R2 test for the optimized RSA model (ad-
justed for optimism), R-ISS, and ISS (not
adjusted for optimism) are described in Table 3;
the C-indices were 0.72, 0.60, and 0.59, respec-
tively (Table 3).
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Fig. 2 Shape of the association of Sb2M (a, b) and
thrombocyte count (c) with overall survival as used in
calculating the risk score in the algorithm. Thrombocyte
count was measured at initiation of 2L treatment at which
the risk of death remains constant, based on curves derived
from fractional polynomials
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Table 3 Performance measures of Cox models for risk stratification algorithm, the International Staging System (ISS) and
the revised ISS
Performance measures Estimatea,b RSA ISS R-ISS
Nagelkerke’s R2 test Original 0.2408 0.0463 0.0801
Adjusting for optimism 0.2269 0.0443 0.0683
C-index Original 0.7316 0.5872 0.6014
Adjusting for optimism 0.7234 0.5872 0.5999
IDI—1 year IDIa New 0.1256 0.1704
IDIb 0.1197 0.1475
95% CIb 0.1009–0.1384 0.0955–0.1994
Increase for eventsb,c 0.0599 0.0519
Decrease for non-eventsb,d 0.0597 0.0956
IDI—2 years IDIa New 0.1564 0.1641
IDIb 0.1480 0.1318
95% CIb 0.1239–0.1720 0.0670–0.1967
Increase for eventsb,c 0.0683 0.0753
Decrease for non-eventsb,d 0.0797 0.0565
IDI—3 years IDIa New 0.1626 0.1426
IDIb 0.1533 0.1092
95% CIb 0.1235–0.1832 0.0155–0.2028
Increase for eventsb,c 0.0601 0.0874
Decrease for non-eventsb,d 0.0933 0.0217
IDI—4 years IDIa New 0.1786 0.1648
IDIb 0.1700 0.1429
95% CIb 0.1365–0.2035 0.0491–0.2367
Increase for eventsb,c 0.0492 0.0456
Decrease for non-eventsb,d 0.1207 0.0973
IDI—5 years IDIa New 0.1708 0.0557
IDIb 0.1629 NAe
95% CIb 0.1164–0.2093
Increase for eventsb,c 0.0403
Decrease for non-eventsb,d 0.1226
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Comparison of RSA Stratification
with that of Existing Risk Algorithms
The performance of the RSA in the RMG data set
was compared with that of the ISS and R-ISS
(Fig. 3). Overlaps were observed in the 95% CIs
for the HRs describing differences in OS
between patients at each of the three ISS-de-
fined disease stages, and a similar pattern was
observed for the R-ISS. However, this was not
the case with the RSA, despite the higher
number of subgroups.
DISCUSSION
We have developed an RSA that is capable of
stratifying patients with MM who have relapsed
and are initiating 2L treatment into four risk
groups with distinct survival expectations.
Multivariable modeling, coupled with guidance
from leading experts in the field, was used to
identify the strongest predictors of OS. Similar
approaches were used to develop the Kattan
prostate cancer nomogram [1], the PREDICT
breast cancer tool [3], the SLE disease activity
indices [4], and the R-ISS [10].
The RSA methodology differs from other risk
assessment tools in the way that risk scores are
calculated. In the RSA, risk scores are calculated
by multiplying the HRs for each predictor; in
comparison, the PREDICT tool, for example,
calculates the prognostic index for each patient
based on the sum of the weighted scores allo-
cated to each of the predictors [3]. Multiplica-
tive scoring is a more robust method for risk
stratification than the commonly used pre-
dicted probabilities because the scores do not
rely on the estimation of a baseline hazard. The
baseline hazard often varies across populations,
resulting in a low accuracy of risk stratification
based on predicted probabilities [29, 30].
The RSA also uses a unique approach for
stratifying patients. The R-ISS was developed
using a KAPS algorithm to match patients with
similar survival expectations with combinations
of predictor variables [10]. In the RSA, KAPS was
used to stratify individual patients according to
Table 3 continued
Performance measures Estimatea,b RSA ISS R-ISS
IDI—6 years IDIa New 0.1461 0.0561
IDIb 0.1390 NAe
95% CIb 0.0738–0.2041
Increase for eventsb,c 0.0316
Decrease for non-eventsb,d 0.1074
C-index Harrell’s concordance index, IDI Integrated discriminations improvement, ISS International Staging System, R-ISS
revised International Staging System, RSA risk stratification algorithm
The IDI considers actual change in calculated risk for individuals separately: those with and without events. The IDI is the
total of IDIevents and IDInon-events (where IDIevents is the difference between the mean of the new and reference model risk
probability for those with the event. Similarly, IDInon-events is the difference in mean probability for those without an event
between reference and new models)
a Original refers to measure calculated using the model fitted to the original data and evaluated on the original data
b Adjusting for optimism refers to measures adjusted for optimism as described in Harrell [28] with number of bootstrap
samples = 1000
c Increase for events = pnew
event
- pold
event; new = RSA continuous; old = model specified in header of the respective column;
p = 1 - probability of surviving
d Decrease for non-events = - (pnew
non-event
- pold
non-event); new = RSA continuous; old = model specified in header of the
respective column; p = 1 - probability of surviving
e Low number of patients without event resulting in zero number of patients without event in one of the bootstrap samples
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Fig. 3 Kaplan–Meier curves and statistics for overall
survival (OS) from initiation of 2L treatment stratified
by risk group by the optimized risk stratification algorithm
(RSA), International Staging System (ISS), and revised ISS
(R-ISS). CI Confidence interval, NE not able to be
evaluated
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their total multiplicative risk score, which
allowed information on several parameters to
be included and the granular nature of contin-
uous variables to be captured.
Many algorithms categorize continuous
variables, and this is the approach that was
followed first; however, a body of evidence
exists to suggest that the categorization of
continuous variables can compromise the
accuracy of predictive models [19, 31]. Treating
the non-categorical parameters as fully contin-
uous variables [1, 3] produced a more accurate
picture of the drivers of disease progression for
patients with MM initiating 2L treatment than a
model in which all variables were categorized.
However, some continuous predictors did not
exhibit a linear relationship with risk of death,
and HRs per unit for Sb2M and thrombocyte
count were derived after variables were trans-
formed mathematically, and these were sup-
ported by expert opinion on the clinical
appropriateness of the thresholds. Defining
threshold values above which the HR remained
constant provided the best balance of statistical
accuracy and clinical utility. This approach
allowed us to account for the plateaus in risk of
death observed with variations in Sb2 M con-
centration and thrombocyte count.
Missing values in the data set were handled
through multiple imputation and the indicator
method, enabling the algorithm to be used in
patients for whom data for all predictive
parameters were not available, including those
for whom there were no CA data. In contrast,
the R-ISS and many other staging and predictive
algorithms are not designed to cope with miss-
ing data. In practice, many patients with MM do
not get tested for high-risk CA and, as a result,
cannot be staged using the R-ISS algorithm.
When assessed in patients with MM initiat-
ing 2L treatment, the Cox model developed for
the optimized RSA performed better than the
ISS or R-ISS Cox models, as measured using
Nagelkerke’s R2 test, the C-index, and IDI. Fur-
thermore, a Kaplan–Meier analysis of OS data
from the initiation of 2L treatment illustrated
that, in the Czech RMG data set, the optimized
RSA stratified patients at first relapse, according
to risk of death, more accurately than either the
ISS or R-ISS.
The RSA methodology has some limitations.
First, while backward selection is a common,
validated method in prognostic model building,
it is somewhat limited by the fact that all vari-
ables must be selected based on clinical signifi-
cance, which can be generally challenging to
assess. Second, further exploration is required to
optimize predictor selection methods when
analyzing multiple imputed data sets. Only one
imputed data set, selected at random, was used,
and this data set was employed to check for
consistency in the other four data sets. Finally,
the patient-specific scores were compared with
those of a theoretical patient who had the
lowest predictor value for each parameter.
Future work could include measurement of the
patient-specific score relative to normal labora-
tory values as baseline values.
Risk group definitions were derived using the
KAPS algorithm only. A mechanism that factors
in expert opinion when defining the boundaries
among risk groups may enhance the clinical
utility of the RSA. Comparisons between the
performance of the optimized RSA and R-ISS
were limited by the number of patients who
were able to be evaluated using R-ISS; only 300
of the 1418 patients in the RMG initiating 2L
treatment could be staged using the R-ISS owing
to the lack of CA data. It must also be
acknowledged that the comparison analysis
between the optimized RSA and ISS and R-ISS
has some limitations as, even though the ISS
and R-ISS are often used in trials in relapsed/
refractory setting, the ISS and R-ISS were not
developed for 2L therapy and have previously
not been validated in the relapsed setting.
The RSA was developed and tested using data
from one country only (Czech Republic). Sev-
eral factors are likely to cause regional varia-
tions in survival outcomes for patients with MM
initiating 2L treatment. Indeed, real-world
studies have shown that treatment patterns and
outcomes for patients with MM vary across
European countries [7, 32]; therefore, the tool
has been validated using data sets from France,
Germany and the UK in further studies (Ha´jek
et al., in preparation).
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CONCLUSIONS
In conclusion, we have developed an RSA to
assess patients with MM at first relapse and to
stratify them into groups with different survival
expectations. Once fully validated, this algo-
rithm may provide a framework to assist
physicians with making treatment decisions
according to survival expectations for patients
with MM who are initiating 2L treatment. The
methodology designed for the construction of
this algorithm has the potential to have wide-
reaching applications and could be used to
create algorithms that predict risk in other dis-
eases that influence survival.
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